{"id":"W3170341220","doi":"10.1200/jco.2021.39.15_suppl.9000","title":"First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Pemetrexed; Internal medicine; Nivolumab; Ipilimumab; Clinical endpoint; Lung cancer; Oncology; Chemotherapy; Cancer; Randomized controlled trial; Cisplatin; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002720371,0.0005142944,0.00121762,0.0003200846,0.0002252683,0.0008233764,0.0008249781,0.0008834074,0.002037524],"category_scores_gemma":[0.001248409,0.0002977355,0.001342487,0.0003766535,0.0003656381,0.0006110368,0.0002859592,0.002004001,0.000353996],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001061514,"about_ca_system_score_gemma":0.0007401772,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001210614,"about_ca_topic_score_gemma":0.006022308,"domain_scores_codex":[0.9995635,0.0002327188,0.00004008739,0.0000589328,0.00006600337,0.00003879524],"domain_scores_gemma":[0.9989781,0.0003405068,0.0003178508,0.00005195521,0.00006586904,0.0002457594],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6849985,0.00811394,0.01549113,0.003403473,0.003530259,0.00009601145,0.0002635801,0.001630817,0.01564269,0.0003068389,0.01041452,0.2561083],"study_design_scores_gemma":[0.5924807,0.2707619,0.1078555,0.0004871839,0.00694348,0.0004696386,0.00011715,0.002239546,0.004071463,0.0003399774,0.01415164,0.00008178664],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9571308,0.03416532,0.0004929554,0.001570817,0.0003425306,0.001062654,0.002572598,0.0001199302,0.002542309],"genre_scores_gemma":[0.9781618,0.01180103,0.001262157,0.001967056,0.0003198435,0.0008812009,0.003719782,0.00002509929,0.001862015],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002720371,"threshold_uncertainty_score":0.01438689,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03096678778541672,"score_gpt":0.3758141077658941,"score_spread":0.3448473199804774,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}